Why the study?
Optimization of antiischemic therapy is necessary in many patients with stable forms of coronary heart disease after or during revascularization.
Does ranolazine improve outcomes in patients with stable coronary heart disease after percutaneous coronary intervention?
Does ranolazine improve outcomes in patients with stable coronary heart disease after percutaneous coronary intervention?
Ranolazine is an effective and safe second-line antianginal therapy for patients with stable ischemic heart disease undergoing PCI, particularly when revascularization is incomplete.
Answers are grounded in this paper and cite their sources.
Supports adjunctive ranolazine post-stenting in stable CAD; leaves open confirmation in prospective outcome trials.
Optimization of antiischemic therapy is necessary in many patients with stable forms of coronary heart disease after or during revascularization. From the standpoint of current guidelines, the addition of second-line drugs, in particular ranolazine, to beta-blockers and/or calcium antagonists is considered during anginal attacks due to incomplete revascularization, to prevent myocardial damage during percutaneous coronary interventions, and in cases when revascularization is not possible. The results of many clinical studies have proven the antiischemic effect and safety of ranolazine after coronary artery stenting. Potential advantages of ranolazine compared with other second-line antianginal drugs are the absence of significant changes in hemodynamic parameters, good tolerability and proven antiarrhythmic effects.
No takes yet. Share an insight, caveat, or question.
Yepanchintseva et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: